Immune responses to respiratory syncytial virus (RSV) vaccines tended to fall short in older people with weakened immunity, a ...

Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity—primarily organ transplant ...

Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity — primarily organ ...

RSV is on the rise across the United States and those who have had it say it’s been particularly debilitating. Here's how to protect youself.

Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...

The respiratory syncytial virus (RSV) vaccine may not protect older adults who are immunocompromised as much as their healthier peers, according to new research.

Mumbai: The recent surge in Human Metapneumovirus (HMPV) cases in China has prompted the state health department to issue a ...

Approximately 40% of participants did not seroconvert or achieve a conservative neutralization threshold post-vaccination.

The study followed 38 immunocompromised adults, aged 64 to 72, who received either the Arexvy or Abrysvo RSV vaccine. Researchers found that people aged 60 and older who are immunocompromised ...

Yearly administration of the influenza vaccine is the main strategy to prevent influenza in immunocompromised patients. Here, we reviewed the recent literature regarding the clinical significance ...

It parallels earlier work done at the center to better understand how the immune systems of people who are immunocompromised respond to vaccines against SARS-CoV-2, the virus that causes COVID-19.